STOCK TITAN

[8-K] Harvard Bioscience Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Harvard Bioscience entered into a retention letter with Interim Chief Financial Officer Mark Frost to support a planned refinancing of its term loan and senior revolving credit facility. The agreement makes Mr. Frost eligible for a $100,000 retention bonus if the refinancing is completed prior to March 15, 2026, replacing a previously offered $50,000 cash bonus. Eligibility requires Mr. Frost to remain employed through the refinancing date and, unless earlier terminated by the company without cause, through the retention date. If terminated without cause before the retention date, Mr. Frost would receive five months of base salary and the company-paid portion of COBRA premiums, subject to execution of a general release. The full Retention Letter Agreement is filed as Exhibit 10.1 and is incorporated by reference.

Harvard Bioscience ha sottoscritto una lettera di retention con l'Amministratore Delegato Finanziario ad interim Mark Frost per supportare il previsto rifinanziamento del suo prestito a termine e della linea di credito revolving senior. L'accordo rende Mr. Frost idoneo a un $100,000 retention bonus se il rifinanziamento viene completato prima del 15 marzo 2026, sostituendo il precedente bonus in contanti di $50,000. L'idoneità richiede che Mr. Frost rimanga impiegato fino alla data del rifinanziamento e, salvo licenziamento anticipato da parte della società senza giusta causa, fino alla data di retention. Se venisse terminato senza giusta causa prima della data di retention, Mr. Frost riceverebbe, subordinatamente alla sottoscrizione di una liberatoria generale, cinque mesi di stipendio base e la quota a carico dell'azienda dei premi COBRA. L'intera Retention Letter Agreement è depositata come Exhibit 10.1 ed è qui incorporata per riferimento.

Harvard Bioscience suscribió una carta de retención con el Director Financiero interino Mark Frost para apoyar la refinanciación prevista de su préstamo a plazo y su línea de crédito revolvente senior. El acuerdo faculta a Mr. Frost para recibir un bono de retención de $100,000 si la refinanciación se completa antes del 15 de marzo de 2026, reemplazando el anterior bono en efectivo de $50,000. Para ser elegible, Mr. Frost debe permanecer empleado hasta la fecha de la refinanciación y, salvo que la compañía lo despida sin causa con anterioridad, hasta la fecha de retención. Si fuera despedido sin causa antes de la fecha de retención, Mr. Frost recibiría, condicionado a la firma de una renuncia general, cinco meses de salario base y la porción de las primas COBRA pagada por la compañía. La totalidad del Retention Letter Agreement se presenta como Exhibit 10.1 y se incorpora por referencia.

Harvard Bioscience는 임시 최고재무책임자 Mark Frost와 보유(리텐션) 서한을 체결하여 기한부 대출 및 선순위 회전 신용시설의 예정된 재융자를 지원하기로 했습니다. 이 계약에 따라 Frost 씨는 재융자가 2026년 3월 15일 이전에 완료되면 $100,000 유지 보너스를 받을 자격이 생기며, 이는 이전에 제안된 $50,000 현금 보너스를 대체합니다. 자격을 얻으려면 Frost 씨가 재융자 완료일까지 그리고 회사가 정당한 사유 없이 조기 해고하지 않는 한 리텐션 날짜까지 고용 상태를 유지해야 합니다. 리텐션 날짜 이전에 정당한 사유 없이 해고되는 경우, Frost 씨는 일반 면책서 서명 조건으로 회사가 부담하는 COBRA 보험료와 함께 기본급 5개월분을 받게 됩니다. 전체 Retention Letter Agreement는 Exhibit 10.1로 제출되어 참조를 위해 포함되어 있습니다.

Harvard Bioscience a conclu une lettre de rétention avec le directeur financier par intérim Mark Frost afin d’appuyer le refinancement prévu de son prêt à terme et de sa facilité de crédit renouvelable senior. L’accord rend M. Frost éligible à un bonus de rétention de $100,000 si le refinancement est finalisé avant le 15 mars 2026, remplaçant un bonus en espèces de $50,000 précédemment proposé. L’éligibilité exige que M. Frost reste en poste jusqu’à la date du refinancement et, sauf licenciement sans motif de la part de la société, jusqu’à la date de rétention. En cas de licenciement sans motif avant la date de rétention, M. Frost percevra, sous réserve de la signature d’une quittance générale, cinq mois de salaire de base et la part des primes COBRA prise en charge par la société. L’intégralité de la Retention Letter Agreement est déposée en tant que Exhibit 10.1 et est incorporée par référence.

Harvard Bioscience hat einen Retentionsbrief mit dem Interims-Finanzchef Mark Frost abgeschlossen, um die geplante Refinanzierung seines Terminkredits und der vorrangigen revolvierenden Kreditfazilität zu unterstützen. Das Abkommen macht Herrn Frost anspruchsberechtigt für einen $100,000 Retentionsbonus, falls die Refinanzierung vor dem 15. März 2026 abgeschlossen wird, und ersetzt einen zuvor angebotenen $50,000 Barbonus. Voraussetzung ist, dass Herr Frost bis zum Abschluss der Refinanzierung beschäftigt bleibt und, sofern die Gesellschaft ihn nicht vorher ohne Grund entlässt, bis zum Retentionsdatum. Wird er ohne Grund vor dem Retentionsdatum gekündigt, erhält Herr Frost, vorbehaltlich der Unterzeichnung eines allgemeinen Verzichts, fünf Monate Grundgehalt sowie den vom Unternehmen gezahlten Anteil der COBRA-Prämien. Das vollständige Retention Letter Agreement ist als Exhibit 10.1 eingereicht und wird hierdurch durch Bezugnahme einbezogen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Retention ties CFO incentives to completing refinancing; direct cost is modest but supports transaction continuity.

The retention bonus increases Mr. Frost's potential cash payout to $100,000, up from the $50,000 previously offered, and is explicitly contingent on completing a refinancing of the company's term loan and senior revolving credit facility before March 15, 2026. This aligns the interim CFO's incentives with a near-term financing objective and may help ensure management continuity during negotiations. The severance protections (five months' base salary plus company-paid COBRA) create a limited termination cost if the company ends the relationship without cause prior to the retention date, subject to a signed release. Overall, the arrangement appears tactical and targeted rather than transformational.

TL;DR: Standard retention and limited severance secure interim CFO continuity for a specific financing milestone; includes customary release condition.

The agreement replaces an earlier, smaller cash incentive with a larger, milestone-driven retention bonus, which is a common practice to retain key financial leadership during critical transactions. Requiring continued employment through the refinancing and conditioning severance on a general release are typical governance protections. The company has disclosed the material terms and filed the full agreement as an exhibit, providing transparency to stakeholders. The terms are narrow in scope and duration, focused on completing the refinancing rather than broader long-term compensation changes.

Harvard Bioscience ha sottoscritto una lettera di retention con l'Amministratore Delegato Finanziario ad interim Mark Frost per supportare il previsto rifinanziamento del suo prestito a termine e della linea di credito revolving senior. L'accordo rende Mr. Frost idoneo a un $100,000 retention bonus se il rifinanziamento viene completato prima del 15 marzo 2026, sostituendo il precedente bonus in contanti di $50,000. L'idoneità richiede che Mr. Frost rimanga impiegato fino alla data del rifinanziamento e, salvo licenziamento anticipato da parte della società senza giusta causa, fino alla data di retention. Se venisse terminato senza giusta causa prima della data di retention, Mr. Frost riceverebbe, subordinatamente alla sottoscrizione di una liberatoria generale, cinque mesi di stipendio base e la quota a carico dell'azienda dei premi COBRA. L'intera Retention Letter Agreement è depositata come Exhibit 10.1 ed è qui incorporata per riferimento.

Harvard Bioscience suscribió una carta de retención con el Director Financiero interino Mark Frost para apoyar la refinanciación prevista de su préstamo a plazo y su línea de crédito revolvente senior. El acuerdo faculta a Mr. Frost para recibir un bono de retención de $100,000 si la refinanciación se completa antes del 15 de marzo de 2026, reemplazando el anterior bono en efectivo de $50,000. Para ser elegible, Mr. Frost debe permanecer empleado hasta la fecha de la refinanciación y, salvo que la compañía lo despida sin causa con anterioridad, hasta la fecha de retención. Si fuera despedido sin causa antes de la fecha de retención, Mr. Frost recibiría, condicionado a la firma de una renuncia general, cinco meses de salario base y la porción de las primas COBRA pagada por la compañía. La totalidad del Retention Letter Agreement se presenta como Exhibit 10.1 y se incorpora por referencia.

Harvard Bioscience는 임시 최고재무책임자 Mark Frost와 보유(리텐션) 서한을 체결하여 기한부 대출 및 선순위 회전 신용시설의 예정된 재융자를 지원하기로 했습니다. 이 계약에 따라 Frost 씨는 재융자가 2026년 3월 15일 이전에 완료되면 $100,000 유지 보너스를 받을 자격이 생기며, 이는 이전에 제안된 $50,000 현금 보너스를 대체합니다. 자격을 얻으려면 Frost 씨가 재융자 완료일까지 그리고 회사가 정당한 사유 없이 조기 해고하지 않는 한 리텐션 날짜까지 고용 상태를 유지해야 합니다. 리텐션 날짜 이전에 정당한 사유 없이 해고되는 경우, Frost 씨는 일반 면책서 서명 조건으로 회사가 부담하는 COBRA 보험료와 함께 기본급 5개월분을 받게 됩니다. 전체 Retention Letter Agreement는 Exhibit 10.1로 제출되어 참조를 위해 포함되어 있습니다.

Harvard Bioscience a conclu une lettre de rétention avec le directeur financier par intérim Mark Frost afin d’appuyer le refinancement prévu de son prêt à terme et de sa facilité de crédit renouvelable senior. L’accord rend M. Frost éligible à un bonus de rétention de $100,000 si le refinancement est finalisé avant le 15 mars 2026, remplaçant un bonus en espèces de $50,000 précédemment proposé. L’éligibilité exige que M. Frost reste en poste jusqu’à la date du refinancement et, sauf licenciement sans motif de la part de la société, jusqu’à la date de rétention. En cas de licenciement sans motif avant la date de rétention, M. Frost percevra, sous réserve de la signature d’une quittance générale, cinq mois de salaire de base et la part des primes COBRA prise en charge par la société. L’intégralité de la Retention Letter Agreement est déposée en tant que Exhibit 10.1 et est incorporée par référence.

Harvard Bioscience hat einen Retentionsbrief mit dem Interims-Finanzchef Mark Frost abgeschlossen, um die geplante Refinanzierung seines Terminkredits und der vorrangigen revolvierenden Kreditfazilität zu unterstützen. Das Abkommen macht Herrn Frost anspruchsberechtigt für einen $100,000 Retentionsbonus, falls die Refinanzierung vor dem 15. März 2026 abgeschlossen wird, und ersetzt einen zuvor angebotenen $50,000 Barbonus. Voraussetzung ist, dass Herr Frost bis zum Abschluss der Refinanzierung beschäftigt bleibt und, sofern die Gesellschaft ihn nicht vorher ohne Grund entlässt, bis zum Retentionsdatum. Wird er ohne Grund vor dem Retentionsdatum gekündigt, erhält Herr Frost, vorbehaltlich der Unterzeichnung eines allgemeinen Verzichts, fünf Monate Grundgehalt sowie den vom Unternehmen gezahlten Anteil der COBRA-Prämien. Das vollständige Retention Letter Agreement ist als Exhibit 10.1 eingereicht und wird hierdurch durch Bezugnahme einbezogen.

false 0001123494 0001123494 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

  

FORM 8-K

_________________

  

CURRENT REPORT

  

Pursuant to Section 13 or 15(d)

of the Securities ExchangeAct of 1934

  

Date of Report (Date of earliest event reported): August 12, 2025

_______________________________

 

 

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

______________________________

 

Delaware   001-33957   04-3306140
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

84 October Hill Road

Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

 

(508) 893-8999

(Registrant's telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

____________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the ExchangeAct (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the ExchangeAct (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the ExchangeAct (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of theAct:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   HBIO   The NASDAQ Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the SecuritiesAct of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 12, 2025, Harvard Bioscience, Inc. (the “Company”) entered into a retention letter agreement (the “Retention Letter Agreement”) with Mark Frost, the Company’s Interim Chief Financial Officer.

 

The Retention Letter Agreement provides that Mr. Frost will be eligible to receive a cash bonus of $100,000 (the “Retention Bonus”) upon successful refinancing of the indebtedness due under the Company’s existing term loan and senior revolving credit facility (the “Refinancing”) prior to March 15, 2026 (the “Retention Date”). Mr. Frost’s eligibility to receive the Retention Bonus is subject to Mr. Frost’s continued employment with the Company through the date of the Refinancing and, unless earlier terminated by the Company without cause, the Retention Date. The Retention Bonus is being offered to Mr. Frost in lieu of the cash bonus of $50,000 provided in Mr. Frost’s offer letter from the Company dated April 10, 2025.

 

The Retention Letter Agreement also requires the Company to provide certain payments and benefits in the event of termination of Mr. Frost’s employment without cause prior to the Retention Date. Such benefits include payment of Mr. Frost’s base salary and payment of the Company’s portion of COBRA premiums, in each case, for a period of five months from the date of termination, subject to Mr. Frost signing a general release of claims.

 

The foregoing description of the Retention Letter Agreement is qualified in its entirety by reference to the complete text of the Retention Letter Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description
10.1 Retention Letter Agreement between Mark Frost and the Company dated August 12, 2025
104 Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

 

 

SIGNATURE

 

 

Pursuant to the requirements of the Securities ExchangeAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    HARVARD BIOSCIENCE, INC.
     
     
     
Date: August 13, 2025   /s/ Mark Frost  
   

Mark Frost

Interim Chief Financial Officer and Treasurer

 

 

 

 

 

 

 

 

 

 

FAQ

What retention payment did Harvard Bioscience (HBIO) offer to Interim CFO Mark Frost?

The company offered a $100,000 retention bonus payable upon successful refinancing of its term loan and senior revolving credit facility.

What is the condition for Mark Frost to receive the HBIO retention bonus?

Mr. Frost must be continuously employed through the date the refinancing is completed and, unless earlier terminated without cause, through the Retention Date of March 15, 2026.

Does the retention agreement replace any previously offered bonus to Mark Frost?

Yes. The $100,000 retention bonus is offered in lieu of a $50,000 cash bonus set forth in Mr. Frost's April 10, 2025 offer letter.

What severance or benefits does Mark Frost receive if terminated without cause before the retention date?

If terminated without cause prior to the retention date, Mr. Frost would receive five months of base salary and payment of the company's portion of COBRA premiums, subject to signing a general release of claims.

Where can I find the full terms of the Retention Letter Agreement?

The complete Retention Letter Agreement is filed as Exhibit 10.1 to the report and is incorporated by reference.
Harvard Biosci

NASDAQ:HBIO

HBIO Rankings

HBIO Latest News

HBIO Latest SEC Filings

HBIO Stock Data

21.33M
40.25M
8.77%
69.59%
2.63%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
HOLLISTON